Serial O +
measurements O +
of O +
antineutrophil O +
cytoplasmic O +
autoantibodies O +
in O +
patients O +
with O +
systemic O +
vasculitis O +
. O +

PURPOSE O +
: O +
To O +
assess O +
the O +
value O +
of O +
serial O +
determinations O +
of O +
antineutrophil O +
cytoplasmic O +
autoantibodies O +
( O +
ANCA O +
) O +
for O +
monitoring O +
disease O +
activity O +
in O +
patients O +
with O +
systemic O +
vasculitis O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
Forty O +
- O +
three O +
patients O +
with O +
histologically O +
proven O +
vasculitis O +
( O +
21 O +
with O +
Wegener O +
's O +
granulomatosis O +
, O +
17 O +
with O +
microscopic O +
polyangiitis O +
, O +
and O +
5 O +
with O +
renal O +
- O +
limited O +
vasculitis O +
) O +
were O +
studied O +
for O +
a O +
median O +
follow O +
- O +
up O +
of O +
22 O +
months O +
. O +

Disease O +
activity O +
was O +
prospectively O +
assessed O +
and O +
quantified O +
by O +
the O +
Birmingham O +
Vasculitis O +
Activity O +
Score O +
. O +

A O +
total O +
of O +
347 O +
sera O +
were O +
analyzed O +
for O +
ANCA O +
determination O +
. O +

RESULTS O +
: O +
Relapses O +
occurred O +
in O +
23 O +
( O +
54 O -
% O +
) O +
of O +
43 O +
patients O +
. O +

Diagnostic O +
category O +
( O +
Wegener O +
's O +
granulomatosis O +
vs O +
micropolyangiitis O +
and O +
renal O +
- O +
limited O +
vasculitis O +
) O +
, O +
severity O +
of O +
initial O +
symptoms O +
( O +
mean O +
vasculitis O +
activity O +
score O +
, O +
mean O +
number O +
of O +
organs O +
involved O +
) O +
, O +
and O +
ANCA O +
pattern O +
[ O +
cytoplasmic O +
- O +
ANCA O +
( O +
c O +
- O +
ANCA O +
) O +
vs O +
perinuclear O +
- O +
ANCA O +
( O +
p O +
- O +
ANCA O +
) O +
] O +
did O +
not O +
significantly O +
differ O +
between O +
relapsers O +
and O +
nonrelapsers O +
. O +

Lung O +
involvement O +
was O +
more O +
frequent O +
at O +
onset O +
among O +
relapsers O +
[ O +
16 O +
of O +
23 O +
( O +
) O +
vs O +
6 O +
of O +
( O +
) O +
; O +
P O +
= O +
0.02 O +
] O +
. O +

Relapses O +
were O +
slightly O +
, O +
but O +
not O +
significantly O +
, O +
more O +
frequent O +
in O +
patients O +
with O +
Wegener O +
's O +
granulomatosis O +
or O +
a O +
c O +
- O +
ANCA O +
pattern O +
. O +

The O +
percentage O +
of O +
relapsers O +
was O +
greater O +
in O +
patients O +
with O +
persistently O +
positive O +
ANCA O +
than O +
in O +
patients O +
with O +
negative O +
or O +
decreasing O +
ANCA O +
titers O +
( O +
86 O -
% O +
vs O +
, O +
P O +
= O +
0.0001 O +
) O +
. O +

However O +
, O +
the O +
predictive O +
value O +
of O +
an O +
increase O +
in O +
ANCA O +
titers O +
for O +
the O +
occurrence O +
of O +
a O +
subsequent O +
relapse O +
was O +
only O +
28 O -
% O +
( O +
4 O +
of O +
14 O +
) O +
for O +
c O +
- O +
ANCA O +
, O +
12 O -
% O +
( O +
2 O +
of O +
17 O +
) O +
for O +
anti O +
- O +
proteinase O +
3 O +
- O +
ANCA O +
, O +
and O +
43 O -
% O +
( O +
6 O +
of O +
14 O +
) O +
for O +
anti O +
- O +
myeloperoxidase O +
- O +
ANCA O +
. O +

An O +
increase O +
in O +
ANCA O +
occurred O +
before O +
or O +
during O +
relapse O +
in O +
33 O -
% O +
( O +
of O +
) O +
of O +
cases O +
for O +
c O +
- O +
ANCA O +
/ O +
anti O +
- O +
proteinase O +
3 O +
antibodies O +
, O +
and O +
73 O -
% O +
( O +
11 O +
of O +
15 O +
) O +
of O +
cases O +
for O +
anti O +
- O +
myeloperoxidase O +
antibodies O +
. O +

CONCLUSION O +
: O +
The O +
persistence O +
of O +
ANCA O +
positivity O +
is O +
strongly O +
associated O +
with O +
relapses O +
. O +

However O +
, O +
an O +
increase O +
in O +
ANCA O +
titers O +
has O +
a O +
poor O +
value O +
for O +
the O +
early O +
prediction O +
of O +
a O +
subsequent O +
relapse O +
and O +
should O +
not O +
be O +
used O +
as O +
a O +
sole O +
parameter O +
for O +
therapeutic O +
intervention O +
. O +

In O +
addition O +
, O +
our O +
results O +
suggest O +
that O +
serial O +
anti O +
- O +
myeloperoxidase O +
determination O +
may O +
be O +
useful O +
as O +
a O +
prognostic O +
marker O +
in O +
patients O +
who O +
are O +
p O +
- O +
ANCA O +
positive O +
. O +

Serum O +
lipid B-Chemical +
and O +
leptin O +
concentrations O +
in O +
hypopituitary O +
patients O +
with O +
growth O +
hormone O +
deficiency O +
. O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
effects O +
of O +
growth O +
hormone O +
( O +
GH O +
) O +
deficiency O +
on O +
serum O +
lipid B-Chemical +
and O +
leptin O +
concentrations O +
in O +
hypopituitary O +
patients O +
taking O +
conventional O +
replacement O +
therapy O +
and O +
to O +
determine O +
the O +
relations O +
between O +
leptin O +
and O +
gender O +
and O +
anthropometric O +
and O +
metabolic O +
variables O +
. O +

SUBJECTS O +
: O +
Twenty O +
- O +
one O +
GH O +
deficient O +
adult O +
hypopituitary O +
patients O +
( O +
15 O +
women O +
, O +
six O +
men O +
) O +
and O +
21 O +
( O +
14 O +
women O +
, O +
seven O +
men O +
) O +
age O +
, O +
sex O +
and O +
body O +
mass O +
index O +
( O +
BMI O +
) O +
matched O +
healthy O +
controls O +
. O +

MEASUREMENTS O +
: O +
After O +
an O +
overnight O +
fast O +
, O +
anthropometric O +
parameters O +
were O +
measured O +
and O +
body O +
composition O +
was O +
determined O +
by O +
a O +
bioelectrical O +
impedance O +
analyser O +
. O +

Venous O +
blood O +
samples O +
were O +
obtained O +
for O +
the O +
measurements O +
of O +
glucose B-Chemical +
, O +
total O +
cholesterol B-Chemical +
, O +
high O +
density O +
lipoprotein O +
( O +
HDL O +
) O +
cholesterol B-Chemical +
, O +
triglyceride B-Chemical +
, O +
intact O +
insulin O +
, O +
insulin O +
- O +
like O +
growth O +
factor O +
1 O +
( O +
IGF O +
- O +
1 O +
) O +
and O +
leptin O +
concentrations O +
. O +

Serum O +
leptin O +
and O +
hormones O +
were O +
analysed O +
by O +
radioimmunoassay O +
. O +

RESULTS O +
: O +
Hypopituitary O +
patients O +
with O +
GH O +
deficiency O +
showed O +
significantly O +
higher O +
triglyceride B-Chemical +
, O +
total O +
and O +
low O +
density O +
lipoprotein O +
( O +
LDL O +
) O +
cholesterol B-Chemical +
and O +
lower O +
HDL O +
cholesterol B-Chemical +
concentrations O +
on O +
conventional O +
replacement O +
therapy O +
. O +

The O +
unfavourable O +
lipid B-Chemical +
profile O +
was O +
particularly O +
evident O +
in O +
women O +
. O +

Significantly O +
higher O +
leptin O +
concentrations O +
were O +
found O +
in O +
patients O +
compared O +
with O +
healthy O +
controls O +
with O +
similar O +
body O +
fat O +
content O +
( O +
23 O +
. O +
5 O -
+ O +
/ O +
- O +
11.8 O +
ng O +
/ O +
ml O +
vs O +
11.7 O +
+ O +
/ O +
- O +
6.9 O +
ng O +
/ O +
ml O +
, O +
P O +
= O +
0.01 O +
) O +
. O +

This O +
difference O +
remained O +
significant O +
even O +
when O +
leptin O +
values O +
were O +
expressed O +
in O +
relation O +
to O +
fat O +
mass O +
percentage O +
( O +
0.79 O +
+ O +
/ O +
- O +
0.40 O +
vs. O +
0.42 O +
+ O +
/ O +
- O +
0.17 O +
ng O +
/ O +
ml O +
% O +
, O +
P O +
< O +
0.05 O +
) O +
and O +
fat O +
mass O +
kg O +
( O +
1.32 O +
+ O +
/ O +
- O +
0.81 O +
vs O +
0.66 O +
+ O +
/ O +
- O +
0.30 O +
ng O +
/ O +
ml O +
kg O +
, O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Significant O +
positive O +
correlations O +
were O +
observed O +
between O +
leptin O +
concentrations O +
and O +
body O +
fat O +
percentage O +
and O +
age O +
in O +
the O +
control O +
group O +
. O +

In O +
patients O +
the O +
sole O +
significant O +
relation O +
between O +
leptin O +
and O +
study O +
parameters O +
was O +
the O +
positive O +
correlation O +
observed O +
between O +
leptin O +
and O +
total O +
cholesterol B-Chemical +
concentrations O +
. O +

Serum O +
leptin O +
concentrations O +
were O +
significantly O +
higher O +
in O +
women O +
than O +
men O +
in O +
the O +
control O +
group O +
, O +
but O +
not O +
in O +
the O +
patients O +
. O +

No O +
significant O +
gender O +
difference O +
was O +
observed O +
when O +
leptin O +
concentrations O +
were O +
expressed O +
in O +
relation O +
to O +
fat O +
mass O +
( O +
percentage O +
and O +
kg O +
) O +
. O +

CONCLUSION O +
: O +
Growth O +
hormone O +
deficient O +
hypopituitary O +
patients O +
( O +
particularly O +
women O +
) O +
on O +
conventional O +
replacement O +
therapy O +
have O +
a O +
more O +
atherogenic O +
lipid B-Chemical +
profile O +
. O +

Leptin O +
concentrations O +
are O +
increased O +
in O +
GH O +
deficient O +
adults O +
even O +
after O +
adjustment O +
for O +
percentage O +
body O +
fat O +
and O +
body O +
fat O +
mass O +
( O +
kg O +
) O +
. O +

Although O +
the O +
nature O +
of O +
our O +
data O +
does O +
not O +
allow O +
us O +
to O +
draw O +
any O +
conclusions O +
on O +
the O +
mechanism O +
( O +
s O +
) O +
of O +
increased O +
leptin O +
concentrations O +
in O +
GH O +
deficiency O +
, O +
decreased O +
central O +
sensitivity O +
to O +
leptin O +
and O +
increased O +
leptin O +
production O +
from O +
per O +
unit O +
fat O +
mass O +
, O +
or O +
alterations O +
in O +
leptin O +
clearance O +
, O +
might O +
be O +
operative O +
. O +

At O +
physiological O +
pH O +
, O +
the O +
spatial O +
arrangement O +
of O +
the O +
three O +
charges O +
of O +
DL B-Chemical +
- I-Chemical +
tetrazol I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
ylglycine I-Chemical +
( O +
5 O +
) O +
could O +
be O +
viewed O +
as O +
similar O +
to O +
those O +
found O +
in O +
certain O +
conformations O +
of O +
the O +
two O +
excitatory O +
amino O +
acids O +
( O +
EAAs O +
) O +
- O +
- O +
aspartic B-Chemical +
and O +
glutamic B-Chemical +
acids I-Chemical +
. O +

Given O +
significant O +
binding O +
to O +
one O +
or O +
more O +
EAA O +
receptors O +
, O +
5 O +
would O +
offer O +
unique O +
modeling O +
and O +
perhaps O +
biological O +
opportunities O +
. O +

We O +
have O +
previously O +
shown O +
it O +
to O +
be O +
the O +
most O +
potent O +
NMDA B-Chemical +
agonist O +
known O +
, O +
with O +
a O +
unique O +
and O +
marked O +
in O +
vitro O +
neutrotoxicity O +
at O +
depolarizing O +
concentrations O +
. O +

Now O +
we O +
report O +
the O +
details O +
required O +
for O +
its O +
synthesis O +
, O +
together O +
with O +
its O +
potency O +
and O +
efficacy O +
in O +
two O +
assays O +
of O +
functional O +
activation O +
of O +
the O +
NMDA O +
receptor O +
, O +
namely O +
agonist O +
- O +
influenced O +
[ B-Chemical +
3H I-Chemical +
] I-Chemical +
MK801 I-Chemical +
binding O +
and O +
agonist O +
- O +
induced O +
release O +
of O +
the O +
neurotransmitter O +
[ B-Chemical +
3H I-Chemical +
] I-Chemical +
- I-Chemical +
norepinephrine I-Chemical +
from O +
brain O +
slices O +
. O +

In O +
both O +
these O +
assays O +
DL B-Chemical +
- I-Chemical +
tetrazol I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
ylglycine I-Chemical +
proved O +
to O +
be O +
more O +
potent O +
and O +
efficacious O +
than O +
NMDA B-Chemical +
and O +
cis B-Chemical +
- I-Chemical +
methanoglutamate I-Chemical +
. O +

It O +
was O +
more O +
potent O +
than O +
, O +
and O +
equally O +
efficacious O +
to O +
, O +
L B-Chemical +
- I-Chemical +
glutamate I-Chemical +
in O +
[ B-Chemical +
3H I-Chemical +
] I-Chemical +
MK801 I-Chemical +
binding O +
. O +

The O +
structural O +
features O +
of O +
5 O +
may O +
well O +
reflect O +
optimal O +
agonist O +
interaction O +
at O +
the O +
NMDA O +
receptor O +
site O +
. O +

( O +
We O +
considered O +
the O +
possibility O +
that O +
some O +
decarboxylation O +
of O +
DL B-Chemical +
- I-Chemical +
tetrazol I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
ylglycine I-Chemical +
may O +
have O +
occurred O +
during O +
testing O +
. O +

This O +
would O +
give O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
aminomethyl I-Chemical +
) I-Chemical +
tetrazole I-Chemical +
( O +
13 O +
) O +
, O +
the O +
tetrazole B-Chemical +
acid I-Chemical +
analog B-Chemical +
of O +
glycine B-Chemical +
; O +
and O +
glycine B-Chemical +
is O +
involved O +
in O +
NMDA O +
receptor O +
activation O +
. O +

Compound O +
13 O +
does O +
not O +
affect O +
[ B-Chemical +
3H I-Chemical +
] I-Chemical +
glycine I-Chemical +
binding O +
at O +
the O +
strychnine B-Chemical +
- O +
insensitive O +
glycine B-Chemical +
binding O +
site O +
, O +
and O +
[ B-Chemical +
3H I-Chemical +
] I-Chemical +
MK801 I-Chemical +
binding O +
studies O +
showed O +
that O +
the O +
( B-Chemical +
aminomethyl I-Chemical +
) I-Chemical +
- I-Chemical +
tetrazole I-Chemical +
, O +
even O +
if O +
is O +
formed O +
, O +
would O +
probably O +
have O +
no O +
effect O +
on O +
the O +
activity O +
of O +
tetrazol B-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
ylglycine I-Chemical +
at O +
the O +
NMDA O +
receptor O +
. O +

Implied O +
preference O +
for O +
seismic O +
design O +
level O +
and O +
earthquake O +
insurance O +
. O +

Seismic O +
risk O +
can O +
be O +
reduced O +
by O +
implementing O +
newly O +
developed O +
seismic O +
provisions O +
in O +
design O +
codes O +
. O +

Furthermore O +
, O +
financial O +
protection O +
or O +
enhanced O +
utility O +
and O +
happiness O +
for O +
stakeholders O +
could O +
be O +
gained O +
through O +
the O +
purchase O +
of O +
earthquake O +
insurance O +
. O +

If O +
this O +
is O +
not O +
so O +
, O +
there O +
would O +
be O +
no O +
market O +
for O +
such O +
insurance O +
. O +

However O +
, O +
perceived O +
benefit O +
associated O +
with O +
insurance O +
is O +
not O +
universally O +
shared O +
by O +
stakeholders O +
partly O +
due O +
to O +
their O +
diverse O +
risk O +
attitudes O +
. O +

This O +
study O +
investigates O +
the O +
implied O +
seismic O +
design O +
preference O +
with O +
insurance O +
options O +
for O +
decisionmakers O +
of O +
bounded O +
rationality O +
whose O +
preferences O +
could O +
be O +
adequately O +
represented O +
by O +
the O +
cumulative O +
prospect O +
theory O +
( O +
CPT O +
) O +
. O +

The O +
investigation O +
is O +
focused O +
on O +
assessing O +
the O +
sensitivity O +
of O +
the O +
implied O +
seismic O +
design O +
preference O +
with O +
insurance O +
options O +
to O +
model O +
parameters O +
of O +
the O +
CPT O +
and O +
to O +
fair O +
and O +
unfair O +
insurance O +
arrangements O +
. O +

Numerical O +
results O +
suggest O +
that O +
human O +
cognitive O +
limitation O +
and O +
risk O +
perception O +
can O +
affect O +
the O +
implied O +
seismic O +
design O +
preference O +
by O +
the O +
CPT O +
significantly O +
. O +

The O +
mandatory O +
purchase O +
of O +
fair O +
insurance O +
will O +
lead O +
the O +
implied O +
seismic O +
design O +
preference O +
to O +
the O +
optimum O +
design O +
level O +
that O +
is O +
dictated O +
by O +
the O +
minimum O +
expected O +
lifecycle O +
cost O +
rule O +
. O +

Unfair O +
insurance O +
decreases O +
the O +
expected O +
gain O +
as O +
well O +
as O +
its O +
associated O +
variability O +
, O +
which O +
is O +
preferred O +
by O +
risk O +
- O +
averse O +
decisionmakers O +
. O +

The O +
obtained O +
results O +
of O +
the O +
implied O +
preference O +
for O +
the O +
combination O +
of O +
the O +
seismic O +
design O +
level O +
and O +
insurance O +
option O +
suggest O +
that O +
property O +
owners O +
, O +
financial O +
institutions O +
, O +
and O +
municipalities O +
can O +
take O +
advantage O +
of O +
affordable O +
insurance O +
to O +
establish O +
successful O +
seismic O +
risk O +
management O +
strategies O +
. O +

Oribatid O +
Mite O +
Communities O +
in O +
the O +
Canopy O +
of O +
Montane O +
Abies O +
amabilis O +
and O +
Tsuga O +
heterophylla O +
Trees O +
on O +
Vancouver O +
Island O +
, O +
British O +
Columbia O +
. O +

To O +
study O +
the O +
oribatid O +
mite O +
community O +
inhabiting O +
microhabitats O +
in O +
the O +
canopy O +
of O +
montane O +
Abies O +
amabilis O +
[ O +
( O +
Douglas O +
ex O +
D O +
. O +

Don O +
) O +
Lindl O +
. O +
] O +
and O +
Tsuga O +
heterophylla O +
[ O +
( O +
Raf O +
. O +
) O +

Sarg O +
] O +
tree O +
species O +
across O +
five O +
elevational O +
sites O +
, O +
we O +
collected O +
branch O +
tips O +
and O +
foliose O +
/ O +
crustose O +
lichen O +
samples O +
over O +
three O +
time O +
periods O +
. O +

Thirty O +
- O +
three O +
species O +
of O +
oribatid O +
mites O +
were O +
identified O +
from O +
the O +
study O +
area O +
. O +

Mite O +
species O +
richness O +
and O +
abundance O +
was O +
significantly O +
affected O +
by O +
microhabitat O +
, O +
and O +
this O +
association O +
was O +
independent O +
of O +
sampling O +
time O +
. O +

At O +
the O +
microhabitat O +
scale O +
, O +
distinct O +
species O +
assemblages O +
were O +
associated O +
with O +
lichen O +
and O +
branch O +
tip O +
habitats O +
, O +
and O +
to O +
a O +
lesser O +
degree O +
, O +
tree O +
species O +
. O +

Conifer O +
specificity O +
was O +
most O +
apparent O +
in O +
the O +
closely O +
related O +
species O +
of O +
Jugatala O +
, O +
where O +
Jugatala O +
tuberosa O +
Ewing O +
was O +
only O +
found O +
on O +
branch O +
tips O +
from O +
A O +
. O +

amabilis O +
and O +
Jugatala O +
sp O +
. O +
was O +
primarily O +
found O +
on O +
branch O +
tips O +
from O +
T O +
. O +

heterophylla O +
. O +

Microhabitat O +
specificity O +
was O +
most O +
pronounced O +
in O +
Dendrozetes O +
sp O +
. O +

where O +
most O +
individuals O +
were O +
found O +
on O +
branch O +
tips O +
and O +
Anachiperia O +
geminus O +
Lindo O +
et O +
al. O +
that O +
occurred O +
primarily O +
on O +
lichens O +
. O +

Principal O +
components O +
analysis O +
of O +
oribatid O +
mite O +
community O +
composition O +
further O +
showed O +
a O +
high O +
degree O +
of O +
association O +
with O +
microhabitat O +
and O +
tree O +
species O +
. O +

Habitat O +
profiles O +
are O +
difficult O +
to O +
discern O +
for O +
many O +
species O +
because O +
tree O +
, O +
microhabitat O +
, O +
and O +
elevation O +
preferences O +
confound O +
distribution O +
patterns O +
. O +

Given O +
the O +
significant O +
tree O +
- O +
microhabitat O +
associations O +
in O +
species O +
composition O +
in O +
this O +
montane O +
canopy O +
study O +
, O +
we O +
suggest O +
that O +
sampling O +
multiple O +
microhabitats O +
across O +
elevations O +
to O +
look O +
for O +
patterns O +
in O +
community O +
structure O +
offers O +
opportunities O +
to O +
explicitly O +
test O +
organizing O +
principles O +
in O +
community O +
ecology O +
. O +

Unilateral O +
hearing O +
disturbance O +
could O +
be O +
an O +
isolated O +
manifestation O +
prior O +
to O +
ipsilateral O +
anterior O +
inferior O +
cerebellar O +
artery O +
infarction O +
. O +

A O +
- O +
year O +
- O +
old O +
man O +
presented O +
with O +
a O +
sudden O +
onset O +
of O +
right O +
- O +
sided O +
hearing O +
disturbance O +
. O +

His O +
hearing O +
disturbance O +
improved O +
gradually O +
, O +
however O +
, O +
dysarthria O +
, O +
right O +
- O +
sided O +
facial O +
weakness O +
and O +
dysesthesia O +
, O +
and O +
gait O +
disturbance O +
was O +
developed O +
11 O +
days O +
after O +
the O +
onset O +
of O +
hearing O +
disturbance O +
. O +

MR O +
imaging O +
revealed O +
fresh O +
infarctions O +
of O +
the O +
right O +
dorsolateral O +
pons O +
and O +
middle O +
cerebellar O +
peduncle O +
localized O +
in O +
the O +
territory O +
of O +
anterior O +
inferior O +
cerebellar O +
artery O +
. O +

Unilateral O +
hearing O +
disturbance O +
could O +
be O +
an O +
isolated O +
manifestation O +
prior O +
to O +
ipsilateral O +
anterior O +
inferior O +
cerebellar O +
artery O +
infarction O +
. O +

The O +
synthesis O +
of O +
2 B-Chemical -
' I-Chemical +
- I-Chemical +
fluoro I-Chemical +
- I-Chemical +
- I-Chemical +
propargyl I-Chemical +
- I-Chemical +
5,8 I-Chemical +
- I-Chemical +
dideazafolic I-Chemical +
acid I-Chemical +
and O +
its O +
2 B-Chemical +
- I-Chemical +
desamino I-Chemical +
, O +
2 B-Chemical +
- I-Chemical +
desamino I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
hydroxymethyl I-Chemical +
, O +
and O +
2 B-Chemical +
- I-Chemical +
desamino I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
methoxy I-Chemical +
analogues B-Chemical +
is O +
described O +
. O +

In O +
general O +
the O +
synthetic O +
route O +
involved O +
the O +
coupling O +
of O +
diethyl B-Chemical +
N I-Chemical +
- I-Chemical +
[ I-Chemical +
2 I-Chemical +
- I-Chemical +
fluoro I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
( I-Chemical +
prop I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
ynylamino I-Chemical +
) I-Chemical +
benzoyl I-Chemical +
] I-Chemical +
- I-Chemical +
L I-Chemical +
- I-Chemical +
glutamate I-Chemical +
with O +
the O +
appropriate O +
6 B-Chemical +
- I-Chemical +
( I-Chemical +
bromomethyl I-Chemical +
) I-Chemical +
quinazoline I-Chemical +
followed O +
by O +
deprotection O +
with O +
mild O +
alkali O +
. O +

These O +
four O +
compounds O +
together O +
with O +
the O +
2 B-Chemical +
- I-Chemical +
desamino I-Chemical +
- I-Chemical +
2 I-Chemical +
- I-Chemical +
methyl I-Chemical +
analogue B-Chemical +
were O +
tested O +
for O +
their O +
activity O +
against O +
L1210 O +
thymidylate O +
synthase O +
( O +
TS O +
) O +
. O +

They O +
were O +
also O +
examined O +
for O +
their O +
inhibition O +
of O +
the O +
growth O +
of O +
the O +
L1210 O +
cell O +
line O +
and O +
of O +
two O +
mutant O +
L1210 O +
cell O +
lines O +
, O +
the O +
L1210 O +
: O +
R7A O +
that O +
overproduces O +
dihydrofolate O +
reductase O +
( O +
DHFR O +
) O +
and O +
the O +
L1210 O +
: O +
1565 O +
that O +
has O +
impaired O +
uptake O +
of O +
reduced O +
folates O +
. O +

Compared O +
with O +
their O +
non O +
- O +
fluorinated O +
parent O +
compounds O +
, O +
the O +
2 B-Chemical -
' I-Chemical +
- I-Chemical +
fluoro I-Chemical +
analogues B-Chemical +
were O +
all O +
approximately O +
2 O +
- O +
fold O +
more O +
potent O +
as O +
TS O +
inhibitors O +
. O +

Similarly O +
, O +
they O +
also O +
showed O +
improved O +
inhibition O +
of O +
L1210 O +
cell O +
growth O +
( O +
1.5 O -
- O -
5 O +
- O +
fold O +
) O +
, O +
and O +
this O +
activity O +
was O +
prevented O +
by O +
co O +
- O +
incubation O +
with O +
thymidine O +
. O +

All O +
had O +
retained O +
or O +
improved O +
activity O +
against O +
both O +
the O +
L1210 O +
: O +
R7A O +
and O +
L1210 O +
: O +
1565 O +
cell O +
lines O +
. O +

N O +
- O +
Methylacetazolamide O +
was O +
shown O +
to O +
be O +
active O +
topically O +
in O +
reducing O +
intraocular O +
pressure O +
( O +
IOP O +
) O +
to O +
a O +
small O +
but O +
statistically O +
significant O +
level O +
in O +
the O +
normotensive O +
rabbit O +
eye O +
. O +

In O +
vivo O +
experiments O +
with O +
N B-Chemical +
- I-Chemical +
methylacetazolamide I-Chemical +
suggest O +
that O +
ocular O +
metabolism O +
to O +
acetazolamide B-Chemical +
was O +
responsible O +
for O +
the O +
observed O +
topical O +
activity O +
. O +

Examination O +
of O +
initial O +
rate O +
kinetics O +
of O +
carbonic O +
anhydrase O +
catalyzed O +
p B-Chemical +
- I-Chemical +
nitrophenyl I-Chemical +
acetate I-Chemical +
hydrolysis O +
showed O +
that O +
N B-Chemical +
- I-Chemical +
methylacetazolamide I-Chemical +
was O +
a O +
competitive O +
inhibitor O +
, O +
in O +
contrast O +
to O +
noncompetitive O +
inhibition O +
seen O +
with O +
acetazolamide B-Chemical +
and O +
other O +
primary O +
sulfonamide B-Chemical +
inhibitors O +
. O +

N B-Chemical +
- I-Chemical +
Substituted I-Chemical +
and O +
unsubstituted B-Chemical +
4 I-Chemical +
- I-Chemical +
chlorobenzene I-Chemical +
- I-Chemical +
and O +
4 B-Chemical +
- I-Chemical +
nitrobenzenesulfonamides I-Chemical +
were O +
also O +
synthesized O +
, O +
and O +
their O +
biochemical O +
characteristics O +
and O +
in O +
vivo O +
ability O +
to O +
lower O +
IOP O +
when O +
applied O +
topically O +
were O +
determined O +
. O +

The O +
primary O +
sulfonamides B-Chemical +
were O +
reversible O +
noncompetitive O +
inhibitors O +
of O +
carbonic O +
anhydrase O +
, O +
with O +
no O +
effect O +
on O +
IOP O +
after O +
topical O +
administration O +
. O +

4 B-Chemical +
- I-Chemical +
Nitrobenzene I-Chemical +
- I-Chemical +
and O +
4 B-Chemical +
- I-Chemical +
chlorobenzenesulfonamides I-Chemical +
containing O +
both O +
N B-Chemical +
- I-Chemical +
hydroxy I-Chemical +
and O +
N B-Chemical +
- I-Chemical +
methyl I-Chemical +
substituents B-Chemical +
were O +
model O +
irreversible O +
inhibitors O +
of O +
carbonic O +
anhydrase O +
and O +
exhibited O +
a O +
trend O +
toward O +
topical O +
activity O +
in O +
reducing O +
IOP O +
in O +
normotensive O +
rabbit O +
eyes O +
. O +

Therefore O +
, O +
this O +
paper O +
describes O +
the O +
synthesis O +
and O +
characterization O +
of O +
two O +
types O +
of O +
carbonic O +
anhydrase O +
inhibitors O +
; O +
the O +
N B-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
substituted I-Chemical +
sulfonamides I-Chemical +
are O +
reversible O +
competitive O +
inhibitors O +
of O +
carbonic O +
anhydrase O +
, O +
while O +
the O +
N B-Chemical +
- I-Chemical +
hydroxy I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
methyl I-Chemical +
- I-Chemical +
substituted I-Chemical +
sulfonamides I-Chemical +
are O +
irreversible O +
inhibitors O +
. O +

This O +
study O +
emphasizes O +
the O +
importance O +
of O +
the O +
metabolic O +
conversion O +
of O +
the O +
enantiomers O +
of O +
3 B-Chemical +
- I-Chemical +
( I-Chemical +
3 I-Chemical +
- I-Chemical +
hydroxyphenyl I-Chemical +
) I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
n I-Chemical +
- I-Chemical +
propylpiperidine I-Chemical +
( O +
3 B-Chemical +
- I-Chemical +
PPP I-Chemical +
) O +
into O +
their O +
catechol B-Chemical +
analogues B-Chemical +
, O +
the O +
enantiomers O +
of O +
3 B-Chemical +
- I-Chemical +
( I-Chemical +
3,4 I-Chemical +
- I-Chemical +
dihydroxyphenyl I-Chemical +
) I-Chemical +
- I-Chemical +
N I-Chemical +
- I-Chemical +
n I-Chemical +
- I-Chemical +
propylpiperidine I-Chemical +
. O +

These O +
isomers O +
are O +
both O +
shown O +
to O +
be O +
excellent O +
substrates O +
for O +
COMT O +
, O +
with O +
a O +
slight O +
preference O +
for O +
the O +
S O +
- O +
( O +
- O +
) O +
enantiomer O +
. O +

Assessment O +
of O +
the O +
dopaminergic O +
activity O +
of O +
these O +
catechols O +
and O +
the O +
results O +
from O +
the O +
determination O +
of O +
brain O +
levels O +
of O +
the O +
enantiomers O +
of O +
3 B-Chemical +
- I-Chemical +
PPP I-Chemical +
and O +
their O +
metabolites O +
indicate O +
that O +
the O +
metabolites O +
probably O +
do O +
not O +
alter O +
the O +
pharmacological O +
profiles O +
established O +
for O +
( B-Chemical +
R I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
+ I-Chemical +
) I-Chemical +
- I-Chemical +
and O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
PPP I-Chemical +
. O +

The O +
conversion O +
of O +
the O +
monophenols B-Chemical +
into O +
catecholic O +
metabolites O +
is O +
only O +
1 O -
- O -
5 O -
% O +
, O +
and O +
the O +
further O +
conversion O +
of O +
these O +
catecholic O +
metabolites O +
into O +
methoxylated O +
analogues O +
is O +
very O +
rapid O +
. O +

However O +
, O +
the O +
very O +
interesting O +
observation O +
was O +
made O +
that O +
, O +
when O +
inhibiting O +
COMT O +
by O +
means O +
of O +
tropolone B-Chemical +
and O +
subsequently O +
treating O +
the O +
rats O +
with O +
high O +
doses O +
of O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
PPP I-Chemical +
( O +
ip O +
) O +
, O +
postsynaptic O +
dopaminergic O +
activity O +
was O +
elicited O +
. O +

This O +
has O +
never O +
been O +
seen O +
for O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
PPP I-Chemical +
without O +
tropolone B-Chemical +
pretreatment O +
and O +
might O +
indicate O +
that O +
, O +
in O +
this O +
special O +
case O +
, O +
the O +
catecholic O +
metabolite O +
affects O +
the O +
in O +
vivo O +
pharmacological O +
profile O +
of O +
( B-Chemical +
S I-Chemical +
) I-Chemical +
- I-Chemical +
( I-Chemical +
- I-Chemical +
) I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
PPP I-Chemical +
. O +

The O +
syntheses O +
and O +
anthelmintic O +
activities O +
of O +
31 O +
3 B-Chemical +
- I-Chemical +
and O +
5 B-Chemical +
- I-Chemical +
( I-Chemical +
isothiocyanatophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
1,2,4 I-Chemical +
- I-Chemical +
oxadiazoles I-Chemical +
are O +
reported O +
. O +

In O +
the O +
primary O +
anthelmintic O +
screen O +
, O +
3 B-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
isothiocyanatophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
1,2,4 I-Chemical +
- I-Chemical +
oxadiazole I-Chemical +
( O +
39 O +
) O +
showed O +
nematocidal O +
activity O +
and O +
3 B-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
furanyl I-Chemical +
) I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
isothiocyanatophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
1,2,4 I-Chemical +
- I-Chemical +
oxadiazole I-Chemical +
( O +
63 O +
) O +
, O +
3 B-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
furanyl I-Chemical +
) I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
chloro I-Chemical +
- I-Chemical +
4 I-Chemical +
- I-Chemical +
isothiocyanatophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
1,2,4 I-Chemical +
- I-Chemical +
oxadiazole I-Chemical +
( O +
64 O +
) O +
, O +
and O +
3 B-Chemical +
- I-Chemical +
( I-Chemical +
2 I-Chemical +
- I-Chemical +
furanyl I-Chemical +
) I-Chemical +
- I-Chemical +
5 I-Chemical +
- I-Chemical +
( I-Chemical +
4 I-Chemical +
- I-Chemical +
chloro I-Chemical +
- I-Chemical +
3 I-Chemical +
- I-Chemical +
isothiocyanatophenyl I-Chemical +
) I-Chemical +
- I-Chemical +
1,2,4 I-Chemical +
- I-Chemical +
oxadiazole I-Chemical +
( O +
66 O +
) O +
showed O +
taeniacidal O +
activity O +
when O +
administered O +
orally O +
to O +
mice O +
. O +

The O +
two O +
most O +
active O +
members O +
of O +
this O +
series O +
, O +
39 O +
and O +
63 O +
, O +
were O +
active O +
against O +
the O +
gastrointestinal O +
nematodes O +
of O +
sheep O +
at O +
mg O +
/ O +
kg O +
. O +

In O +
addition O +
, O +
39 O +
was O +
also O +
found O +
to O +
be O +
active O +
against O +
hookworms O +
in O +
dogs O +
at O +
a O +
single O +
, O +
oral O +
dose O +
of O +
mg O +
/ O +
kg O +
. O +

